Synta's lung cancer drug ganetespib wins fast-track status from FDA

09/16/2013 | Pharmaceutical Business Review Online

The FDA granted fast-track designation to Synta Pharmaceuticals' ganetespib, which is being developed as a therapy for metastatic nonsmall-cell lung adenocarcinoma. The drug, a heat shock protein 90 inhibitor, is in a midstage and late-stage trial program.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL